[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650889":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":16,"locations":25,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Hospital Tuebingen","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Patients with higher grade aortic stenosis",null,[12],{"name":13,"affiliation":14,"role":15},"Patrick Krumm, Prof. Dr. med.","University Hospital of Tuebingen","PRINCIPAL_INVESTIGATOR",[17,21],{"name":13,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+49 7071 29 68119","patrick.krumm@med.uni-tuebingen.de",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Studienzentrum Bildgebung Radiology","+49 7071 29 85251","studienzentrum-radiologie@med.uni-tuebingen.de",[26],{"facility":14,"status":27,"city":28,"state":10,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Tübingen","72076","Germany","DE",{"type":33,"coordinates":34},"Point",[35,36],9.05222,48.52266,{"lat":36,"lon":35},[39],{"name":40,"role":18,"phone":41,"phoneExt":10,"email":42},"Jan M. Brendel, PD Dr. med.","+49 7071 29 68528","jan.brendel@med.uni-tuebingen.de",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46],{"name":47,"class":48},"Bayer","INDUSTRY","100650889","non-interventional-study-on-the-prevalence-of-cardiac-amyloidosis-in-patients-with-higher-grade-aortic-valve-stenosis---evaluation-using-echocardiography-computed-tomography-tc99-spectct-and-cardiac-magnetic-resonance-imaging-cmr-100650889",false,"NCT07752732","Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT\u002FCT and Cardiac Magnetic Resonance Imaging (CMR)","NIS-TAVI-AMY","Inclusion Criteria:\n\n* Patients with severe aortic valve stenosis (valve opening area \\\u003C1 cm², pmean \\>40 mmHg, Vmax \\>4 m\u002Fsec)\n* Suspected cardiac amyloidosis\n* Performance of one or more of the following imaging examinations due to (justifiable) clinical indication: echocardiography, photon-counting computed tomography (CT), Tc99-SPECT\u002FCT, cardiac MRI\n* Age ≥18 years\n* Written consent of the patient for prospective data collection regarding Tc99-SPECT\u002FCT, CT, and, if applicable, CMR and follow-up\n\nExclusion Criteria:\n\n• patients unable to give consent","ALL","18 Years",{"count":59,"type":60},600,"ESTIMATED","OBSERVATIONAL","Degenerative aortic stenosis (AS) is frequently accompanied by left ventricular hypertrophy and diastolic dysfunction, features that overlap with transthyretin (ATTR) cardiac amyloidosis. Because concomitant cardiac amyloidosis may adversely affect outcomes after transcatheter aortic valve implantation (TAVI), its early detection is clinically important.\n\nThis prospective observational study aims to evaluate multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation. Clinically indicated technetium-99m phosphonate SPECT\u002FCT and CT will be used to assess the presence and extent of cardiac amyloidosis, including quantitative measures of myocardial tracer uptake and extracellular volume. In patients with abnormal findings, cardiac magnetic resonance imaging (CMR) will be performed as an additional non-invasive imaging modality according to institutional clinical practice.\n\nThe study will determine the prevalence of cardiac amyloidosis in this population and investigate the diagnostic and prognostic value of imaging-derived quantitative parameters. Standardized clinical follow-up at 6, 12, and 24 months will assess associations between imaging biomarkers and clinical outcomes. The study is observational and does not alter routine clinical management or diagnostic pathways.",[64,65,66],"Amyloidosis Cardiac","Stenosis Coronary","TAVI(Transcatheter Aortic Valve Implantation)",[68,69,70,71,72,73,74,75,76],"Amyloidosis","aortic valve stenosis","stenosis","cardiac","cardiac MRI","SPECT\u002FCT","photon counting CT","valve implantation","TAVI","2026-08-03",{"date":79,"type":80},"2026-08-07","ACTUAL",{"date":82,"type":80},"2020-01-14",{"date":84,"type":60},"2028-06-30",{"name":5,"class":6},1]